Cerenome is trading 10.1% lower at $1.60, with no clear October 2 company-specific catalyst identified. - Lake Street lowered its price target from $50 to $31 on October 1, maintaining a Buy rating. Revised assumptions included dilution from the financing facility, but reporting does not establish that this action caused the October 2 move. - Major indices were higher in the supplied market data while healthcare was weaker. Cerenome posted investor-presentation slides October 2, but no link to the decline was established.